Brown Adipose Tissue in Humans Is Activated by Elevated Plasma Catecholamines Levels and Is Inversely Related to Central Obesity

Qidi Wang1,2,*, Min Zhang3,*, Guang Ning1,2, Weiqiong Gu1,2, Tingwei Su1,2, Min Xu1,2, Biao Li3, Weiqing Wang1,2

1 Shanghai Key Laboratory for Endocrine Tumors and Key Laboratory for Endocrine and Metabolic Diseases of Chinese Health Ministry, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China, 2 Shanghai Clinical Center for Endocrine and Metabolic Diseases and Division of Endocrinology and Metabolism of The E-Institute of Shanghai Universities, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China, 3 Department of Nuclear Medicine, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China

Abstract

Background: Recent studies have shown that adult human possess active brown adipose tissue (BAT), which might be important in controlling obesity. It is known that β-adrenergceptor-UCP1 system regulates BAT in rodent, but its influence in adult humans remains to be shown. The present study is to determine whether BAT activity can be independently stimulated by elevated catecholamines levels in adult human, and whether it is associated with their adiposity.

Methodology/Principal Findings: We studied 14 patients with pheochromocytoma and 14 normal subjects who had performed both 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and plasma total metanephrine (TMN) measurements during 2007–2010. The BAT detection rate and the mean BAT activity were significantly higher in patients with elevated TMN levels (Group A: 6/8 and 6.7 ± 2.1 SUVmean- g/ml) than patients with normal TMN concentrations (Group B: 0/6 and 0.4 ± 0.04 SUVmean- g/ml) and normal subjects (Group C: 0/14 and 0.4 ± 0.03 SUVmean-g/ml). BAT activities were positively correlated with TMN levels (R = 0.83, p < 0.0001) and were inversely related to body mass index (R = −0.47, p = 0.010), visceral fat areas (R = −0.39, p = 0.044), visceral/totat fat areas (R = −0.52, p = 0.0043) and waist circumferences (R = −0.43, p = 0.019). Robust regression revealed that TMN (R = 0.81, p < 0.0001) and waist circumferences (R = −0.009, p = 0.009) were the two independent predictors of BAT activities.

Conclusions/Significance: Brown adipose tissue activity in adult human can be activated by elevated plasma TMN levels, such as in the case of patients with pheochromocytoma, and is negatively associated with central adiposity.

Introduction

Mammals have two types of adipose tissue that control whole-body energy metabolism, the well-understood white adipose tissue for energy storage [1] and brown adipose tissue (BAT) for cold- and diet-induced thermogenesis [2]. BAT thermogenesis is dependent on the β-adrenergically mediated activation of lipolysis and subsequent degradation of fatty acids via uncoupling protein 1 (UCP1) that dissipate large amounts of chemical energy as heat [3]. Brown adipose tissue is most obvious in small mammals and infant humans, but was often believed to be lost postnataally within the first few years of human life [2]. Recent studies using positron emission tomography and computed tomography (PET/CT) have demonstrated that healthy adult humans do possess significant depots of metabolically active BAT [4,5,6], which is acutely cold-induced [5,6] and is inversely correlated with body mass index (BMI) and age [4,5]. Although several BAT-influencing factors have been identifed [4,5,6], the role of β-adrenergceptor-UCP1 system- which is functional in rodents in regulating BAT activity [2]- has not yet been fully studied in adult humans. In rodents, it is found that the sensation of cold causes sympathetic nerve terminals in the brown adipose tissue to release catechole-amines thatstimulate BAT proliferation and activation [2]. In addition, brown fat activity can be activated by β-adrenergic activator or catecholamines, and causes the emergence of UCP-1 expressing BAT in classic depots of white fat [7,8]. In light of these observations, we compared BAT activities, long-lived catecholamine metabolites, i.e. plasma metanephrine and normetanephrine concentrations, as well as body fat parameters in normal subjects and patients with pheochromocytoma, a neuroendocrine
tumor intermittently secretes excessive amounts of catecholamines. Our present data demonstrate that BAT activity is strongly and positively correlated with catecholamines concentrations in the subjects, and is negatively related with their adiposity, especially waist circumferences; suggesting an important role of adrenoreceptor-UCP1 system in the regulation of active BAT and subsequent central obesity in adult human.

Methods

Ethics statement
This study was approved by the Institutional Review Board of the Rui-jin Hospital Affiliated to Shanghai Jiao-Tong University School of Medicine and was in accordance with the principle of the Helsinki Declaration II. The written informed consent was obtained from each participant.

Subjects
From all pheochromocytoma patients diagnosed during 2007–2010 at Shanghai Clinical Center for Endocrine and Metabolic Diseases, fourteen have performed consecutive 18F-fluorodeoxyglucose (18F-FDG) PET/CT whole-body scans. These patients were confirmed by postoperative pathology. Fourteen age- and BMI-matched healthy volunteers were also recruited for the study. Data on age, sex, weight, height, fasting glucose, triglyceride, cholesterol and thyroid hormone levels, medication use were obtained for all subjects.

In the present study, plasma catecholamines level was represented by its long-lived metabolic products, i.e. plasma metanephrine (MN) and normetanephrine (N MN) created by action of catechol-O-methyl transferase on epinephrine and norepinephrine, determined by reverse-phase high-performance liquid chromatography (HPLC) (Agilent 1100 series, Santa Clara USA) with electrochemical detection (ESA-A Dionex Company, Chelmsford USA) as previously described [9,10]. In our earlier study on 40 healthy volunteers, plasma concentrations of MN ranged between 10.3 and 78.2 ng/L (mean 39.9±16.6 ng/L), and N MN between 17.5 and 118.8 ng/L (mean 61.1±35.6 ng/L). Thus, using the upper 2SD as cut-off points, the subjects can be classified into three groups: 5 pheochromocytoma patients with high total metanephrine (TMN: MN+N MN) (>185 ng/L, Group A), 6 pheochromocytoma patients with normal TMN (<185 ng/L, Group B) and 14 normal controls (Group C).

Brown adipose tissue activity by PET/CT scan
All of the subjects were studied in the morning after an overnight fast beginning around 10 p.m. the night before. The blood glucose concentration of each subject was controlled under the level of 7.4 mmol/L before 18F-FDG (4.44–5.55 MBq/kg) was injected intravenously. They were kept under thermoneutral conditions (23–25°C) for at least 1 h after injection. Later the 18F-FDG PET/CT scans were performed with a GE Discovery STE16 integrated PET/CT scanner combining the ability to acquire CT images and PET data of the same subject in one session. The whole-body CT data were acquired by a continuous CT scan, N2 system, Osaka, Japan. Visceral/total fat areas (V/T) was described procedure [12]. The intra-abdominal visceral fat areas (VFA), subcutaneous fat areas (SFA), and waist circumferences (WC) were measured with image analysis software package (Fat scan, N2 system, Osaka, Japan).

PET and CT images were coregistered and analyzed by a GE AW workstation with PET/CT Volume Viewer software. Two experienced blinded observers assessed the FDG uptake, particularly in both sides of the neck and paravertebral regions, by visually judging the radioactivity greater than background [1]. In parallel, the activity of BAT was quantified by mean standardized uptake values (SUVmean · g/ml) [4] which is an automatic method based on GE AW workstation [11]. The standardized uptake values, defined as the activity per milliliter within the region of interest divided by the injected dose in megabecquerels per kilogram of body weight was determined [4]. Calculations were performed using PET/CT Volume Viewer software.

Visceral/subcutaneous fat areas and waist circumferences
Abdominal fat distribution was examined at the umbilicus level in the supine position using CT, according to the previously described procedure [12]. The intra-abdominal visceral fat areas (VFA), subcutaneous fat areas (SFA), and waist circumferences (WC) were measured with image analysis software package (Fat scan, N2 system, Osaka, Japan). Visceral/total fat areas (V/T) was calculated as VFA/(VFA+SFA) ×100%.

Statistics
Statistical analysis was performed with SAS 9.2 (SAS Institute, Cary NC). All continuous parameters were summarized as means±SD, and all categorical parameters were summarized as proportions. To compare between-group differences, robust ANOVA was performed to compare difference in BAT activity between groups [13]. A conventional linear regression model was used to explore the association between BAT activity and other parameters, such as TMN, BMI, VFA, SFA, V/T and WC. To minimize the impact of outliers on regression estimators, robust regression analysis was performed to identify factors that are independently associated with BAT [13]. The P-values reported were two-sided. A P-value of less than 0.05 indicated statistical significance.

Results
Information on all pheochromocytoma patients to Shanghai Clinical Center for Endocrine and Metabolic Diseases between 2007 and 2010 was recorded and collated on an intra-hospital database. This database contained information on clinical details, biochemical examination, imaging records and pathology results. Based on this database, we extracted records of all patients with pheochromocytoma that have performed PET/CT whole-body scans. All of the patients presented clinical findings of hypertension, associated with positive results in PET/CT, and finally confirmed by post-operative pathology. Among them, eleven cases (80%) were adrenal pheochromocytoma and three cases (20%) were from extra-adrenal chromaffin tissues. Two patients were reported as metastatic disease. Plasma total metanephrine (TMN) levels were significantly higher in eight patients with pheochromocytoma (Group A: 2403±1189 ng/L, Table 1) than the other 6 patients (Group B: 122±12 ng/L, Table 1) and normal subjects (Group C: 116.4±8.1 ng/L, Table 1). Serum fasting glucose, triglyceride, cholesterol and thyroid hormone levels (FT3, FT4) were comparable within three groups (Table 1). None of the subjects have taken β-adrenergic blockers at the time of PET scan.

On the fused PET/CT images, the brown adipose tissue was located not in muscle tissue but in fat tissue, within the neck, supraclavicular and paravertebral region (Fig. 1D) as previously reported [4,5,6]. Six out of eight patients from Group A had
evidence of brown adipose tissue (Figure 1A, Table 1). Only two patients had no 18F-FDG uptake in areas of adipose tissue. These two subjects either had the highest BMI, total fat areas or lowest TMN levels. On the contrary, there was no detectable brown adipose tissue in any of the subjects with normal TMN concentrations irrespective of their pheochromocytoma disease background (Fig. 1B-C, Table 1). Similar results were observed when the mean BAT activity was taken into account: it was significantly higher in Group A patients (6.7 ± 2.1 SUVmean g/ml) than that in Group B (0.4 ± 0.04* g/ml, R = 0.04*, p = 0.010) and Group C (0.4 ± 0.03 SUVmean g/ml, p < 0.0001) (Table 1). No significant difference in BAT activity was observed between Group B and Group C that presented comparable TMN levels (Table 1). These data suggest that circulating catecholamines level, rather than the disease itself, might determine BAT activity in pheochromocytoma patients.

We further performed a conventional linear regression to explore the association between BAT activities and TMN concentrations in our subjects. For the first time, we demonstrated a strong and significantly positive correlation between BAT activities and TMN levels (both in log scale; R = 0.83, p < 0.0001, Fig. 2). These results indicate that BAT activity can be strongly induced by increased adrenergic input in adult humans, as in the case of patients with pheochromocytoma.

It has been reported that the amount of brown adipose tissue is inversely related to body mass index (BMI) in adult human [4,6]. In the present study, we included not only BMI but also other parameters, such as visceral fat areas, subcutaneous fat areas, visceral/total fat areas and waist circumferences, which measured abdominal fat volume and distribution [12]. Pearson correlation test revealed that LogBAT was negatively correlated with BMI (R = -0.47, p = 0.010), visceral fat areas (R = -0.39, p = 0.044), visceral/total fat areas (R = -0.52, p = 0.0043), waist circumferences (R = -0.43, p = 0.019), but not with subcutaneous fat areas (R = -0.15, p = 0.45). In the next step, robust regression analysis was performed to identify factors that were independently associated with BAT (log scale) [13]. Among age, sex, BMI, VFA, SFA, V/T, WC, and TMN examined, only TMN (R = 0.81, p < 0.0001) and waist circumferences (R = -0.009, p = 0.009) were found independently associated with BAT activity (Table 2).

**Discussion**

It was normally believed that brown fat is present only in fetuses and infants and diminishes in adults [2], however recent studies have clearly demonstrated that adults do possess metabolically active brown fat which can be detected by PET/CT imaging and be stimulated by cold exposure [4,5,6]. Moreover, the observation that the amount of BAT is inversely correlated with body mass index [1,4,5], have led to an increased interest in the potential importance of BAT in regulating body weight and as a potential target for treating obesity [1,4,5,6]. With this knowledge of BAT, targeted therapies are under study, by either induction of already available BAT (with β-adrenergic activator) [14,15] or changing the genetic structure for differentiating tissue from the preadipocyte phase to BAT [16,17].

From studies performed in vitro, catecholamines have been suggested to play a prime role modulating not only brown preadipocyte proliferation, mature brown adipocytes differentiation, but also their apoptosis [2]. The present study now shows that the circulating total metanephrines, long-lived catecholamines metabolites levels and BAT activities were simultaneously elevated in patients with pheochromocytoma under thermoneutral conditions. These data suggest that the catecholamines such as epinephrine and norepinephrine might stimulate BAT activity, which is supported by the following evidence. First, 6 of 14 patients

---

**Table 1. Characteristics of the subjects.**

| Characteristic | Pheochromocytoma patients | Normal subjects |
|---------------|---------------------------|-----------------|
| Age (Yr)      | 37.8 ± 4.9                | 45.8 ± 4.8      | 46.9 ± 2.4      |
| Detectable Brown-adipose-tissue | 6/8                      | 0/6             | 0/14            |
| Brown-adipose-tissue | 6.7 ± 2.1                 | 0.4 ± 0.04*     | 0.4 ± 0.03*     |
| Total metanephrines (TMN, ng/L) | 2403 ± 1189              | 122 ± 12*       | 116 ± 8.1*      |
| Body mass index | 22.4 ± 1.0                | 23.6 ± 1.6      | 23.9 ± 0.6      |
| Visceral Fat Areas | 50.7 ± 9.2               | 91.5 ± 34.3     | 85.7 ± 13.6     |
| Subcutaneous Fat areas | 161.5 ± 15.5             | 217.5 ± 37.1    | 127.1 ± 12.3    |
| Waist circumferences | 83.8 ± 3.3               | 93.6 ± 5.7      | 86.4 ± 2.0      |
| Fasting blood glucose (mM) | 5.6 ± 0.5                | 5.3 ± 0.4       | 5.3 ± 0.2       |
| Triglyceride (mM) | 1.3 ± 0.3                | 1.3 ± 0.2       | 1.5 ± 0.3       |
| Cholesterol (mM) | 4.7 ± 0.2                | 4.8 ± 0.5       | 4.4 ± 0.3       |
| Free T3 (pM)    | 4.1 ± 0.2                | 3.9 ± 0.4       | 4.0 ± 0.2       |
| Free T4 (pM)    | 12.5 ± 0.5               | 12.3 ± 0.7      | 13.5 ± 0.5      |

1 Brown adipose tissues activity was quantified by mean standardized uptake values (SUVmean g/ml) by PET/CT.
2 Total metanephrines were calculated as metanephrine (MNE) plus normetanephrine (NMN).
3 Body mass index was calculated as weight in kilograms divided by height in meters squared.
4 Visceral fat areas, subcutaneous fat areas and waist circumferences were examined at the umbilicus level in the supine position using CT.

*compared to pheochromocytoma patients with high TMN (Group A), p < 0.001.

doi:10.1371/journal.pone.0021006.t001
with pheochromocytoma showed a substantial FDG uptake into adipose tissue of the supraclavicular and paraspinal regions, whereas no detection was found in normal controls. Second, all the BAT positive patients were presenting elevated TMN levels, while none of the patients with normal TMN had brown adipose tissue detections, indicating that BAT activity is hormone-dependent, rather than disease-specific. Third, we were the first to provide a strong and positive correlation between BAT activity and circulating TMN concentration ($r = 0.83$, $p < 0.0001$), thus undoubtedly demonstrated that BAT activity could be activated adrenergically in humans. Fourth, TMN was the strongest predictor of BAT activity, independent of other influencing factors such as age, sex, BMI, and fat distribution. The present finding is consistent with several earlier case reports by nuclear medicine physicians: an increased glucose uptake was observed in a 50-year-old male patient with adrenal pheochromocytoma [18] and a disappearance of prominent FDG uptake in BAT was found in a 25-year-old woman with mediastinal pheochromocytoma after the tumor resection [19]. A more detailed finding by Hadi et al reported 26 (27.0%) of 96 patients with known or suspected pheochromocytoma showed BAT evaluated with $^{18}$F-FDA or $^{18}$F-FDG PET/CT [20]. However,
These studies failed to further investigate the direct relationship between catecholamines levels and BAT activation. Taken together, brown fat in adult human can be activated and can expand quite massively due to catecholamines over-secretion, proving a central role of adrenergic activation in BAT regulation.

It is well established that catecholamines-mediated effects on energy expenditure and alterations in the efficiency of carbohydrate metabolism are possible mediators of changes in body weight. Catecholamines can increase fat lipolysis and reduce adipogenesis or the creation of new fat [21] and this effect is attenuated in the subcutaneous adipose tissue of obese subjects [22,23]. Our finding that catecholamines-associated brown adipose tissue activation might provide additional explanation on the impact of these hormones on body weight control. Early evidence for BAT as a tissue affecting adiposity in rodents came from animals with surgically denervated interscapular BAT [24] or transgenic mice expressing β3-adrenergic receptor in many adult humans, and our evidence that there is a significant amount of brown adipose tissue [14,15,34,35], but not yet approved in humans. The recent finding that their activity can indeed be stimulated by expressing β3-adrenergic receptor in many adult humans, and our evidence that there is a significant amount of brown adipose tissue [14,15,34,35], but not yet approved in humans. The recent evidence that there is a significant amount of brown adipose tissue expressing β3-adrenergic receptor in many adult humans, and our current finding that their activity can indeed be stimulated by adrenergic input and is inversely related with visceral fat volume, might offer new hope in searching for intriguing target for the control of whole-body energy balance and obesity.

Table 2. Robust regression analysis to identify factors that are independently associated with brown-adipose-tissue activity.

| Factor          | Initial model | Final model |
|-----------------|---------------|-------------|
| β ± SE          | P-value       | β ± SE      | P-value |
| Age             | 0.002 ± 0.004 | 0.61        |         |
| Male sex        | 0.04 ± 0.09   | 0.72        |         |
| BMI             | -0.010 ± 0.026 | 0.67     |         |
| VFA             | 0.0002 ± 0.002 | 0.93     |         |
| SFA             | 0.001 ± 0.002 | 0.63        |         |
| WC              | -0.02 ± 0.20  | -0.009 ± 0.003 | 0.009 |
| V/T             | 0.74 ± 0.96   | 0.44        |         |
| Log (TMN)       | 0.91 ± 0.09   | <0.0001     | 0.81 ± 0.06 | <0.0001 |

Robust regression analysis was performed to identify factors that are independently associated with brown-adipose-tissue (BAT, log scale). An initial robust regression model included age, sex, body mass index (BMI), visceral fat areas (VFA), subcutaneous fat areas (SFA), waist circumferences (WC), visceral/total fat areas (V/T) and log (TMN). Those variables that did not make significant contributions to the models were deleted in a stage-wise manner, yielding the final models. The final model is shown including 2 significant predictors, Log(TMN) and waist circumferences.

References

1. Saito M, Okamatsu-Ogura Y, Matsushita M, Watanabe K, Yoneshiro T, et al. (2009) High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. Diabetes 58: 1526–1531.
2. Cannon B, Nedergaard J (2004) Brown adipose tissue: function and physiological significance. Physiol Rev 84: 277–359.
3. Lowell BB, Spiegelman BM (2000) Towards a molecular understanding of adaptive thermogenesis. Nature 404: 652–660.
4. Cypress AM, Lehman S, Williams G, Tal I, Rodman D, et al. (2009) Identification and importance of brown adipose tissue in adult humans. N Engl J Med 360: 1509–1517.
5. Van Marken Lichtenbelt WD, Vanhoomerig JW, Smulders NM, Drossaerts JM, Kemenerki GJ, et al. (2009) Cold-activated brown adipose tissue in healthy men. N Engl J Med 360: 1500–1508.
6. Virtanen RA, Lidell ME, Orava J, Heglin M, Westergren R, et al. (2009) Functional brown adipose tissue in healthy adults. N Engl J Med 360: 1518–1525.
7. Cinti S (2003) The adipocyte organ. Prostaglandins Leukot Essent Fatty Acids 73: 9–15.
8. Ghorbani M, Himms-Hagen J (1997) Appearance of brown adipocytes in white adipose tissue during CL 316,243-induced reversal of obesity and diabetes in Zucker fa/fa rats. Int J Obes Relat Metab Disord 21: 465–475.
9. Virtanen RA, Lidell ME, Orava J, Heglin M, Westergren R, et al. (2009) Functional brown adipose tissue in healthy adults. N Engl J Med 360: 1518–1525.
10. Cinti S (2003) The adipocyte organ. Prostaglandins Leukot Essent Fatty Acids 73: 9–15.
11. Ghorbani M, Himms-Hagen J (1997) Appearance of brown adipocytes in white adipose tissue during CL 316,243-induced reversal of obesity and diabetes in Zucker fa/fa rats. Int J Obes Relat Metab Disord 21: 465–475.
9. Lenders JW, Eisenhofer G, Armando I, Keiser HR, Goldstein DS, et al. (1993) Determination of metanephrines in plasma by liquid chromatography with electrochemical detection. Clin Chem 39: 97–103.
10. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, et al. (2002) Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 287: 1427–1434.
11. (2005) GE Medical Systems Volume Viewer 2 User Guide 5135930-100 Revision 2. pp 399–401.
12. Yoshizumi T, Nakamura T, Yamane M, Islam AH, Menju M, et al. (1999) Abdominal fat: standardized technique for measurement at CT. Radiology 211: 283–286.
13. Andersen R (2008) Modern Methods for Robust Regression. Sage University Paper Series on Quantitative Applications in the Social Sciences. pp 07–152.
14. Arch JR, Wilson S (1996) Prospects for beta 3-adrenoceptor agonists in the treatment of obesity and diabetes. Int J Obes Relat Metab Disord 20: 191–199.
15. Lowell BB, Bachman ES (2003) Beta-Adrenergic receptors, diet-induced thermogenesis, and obesity. J Biol Chem 278: 29305–29308.
16. Kajimura S, Seale P, Spiegelman BM Transcriptional control of brown fat development. Cell Metab 11: 257–262.
17. Fruhbeck G, Becerril S, Sainz N, Garrastachu P, Garcia-Velloso MJ (2009) BAT: a new target for human obesity? Trends Pharmacol Sci 30: 387–396.
18. Yamaga LY, Thom AF, Wagner J, Baroni RH, Hidal JT, et al. (2008) The effect of catecholamines on the glucose uptake in brown adipose tissue demonstrated by [18]F-FDG PET/CT in a patient with adrenal pheochromocytoma. Eur J Nucl Med Mol Imaging 35: 446–447.
19. Kuji I, Inabayashi E, Minagawa A, Matsuda H, Miyachi T (2008) Brown adipose tissue expressing intense FDG uptake in a patient with mediastinal pheochromocytoma. Ann Nucl Med 22: 231–235.
20. Hadji M, Chen CC, Whalley M, Pacak K, Carrasquillo JA (2007) Brown fat imaging with [18]F-6-fluorodopamine PET/CT, [18]F-FDG PET/CT, and [123]I-MIBG SPECT: a study of patients being evaluated for pheochromocytoma. J Nucl Med 48: 1077–1083.
21. Lofgren P, Hoffscheidt J, Naslund E, Wiren M, Arner P (2005) Prospective and controlled studies of the actions of insulin and catecholamine in fat cells of obese women following weight reduction. Diabetologia 48: 2354–2362.
22. Large V, Arner P (1998) Regulation of lipolysis in humans. Pathophysiological modulation in obesity, diabetes, and hyperlipidemia. Diabetes Metab 24: 409–418.
23. Coppack SW, Jensen MD, Miles JM (1994) In vivo regulation of lipolysis in humans. J Lipid Res 35: 177–193.
24. Dulloo AG, Miller DS (1984) Energy balance following sympathetic denervation of brown adipose tissue. Can J Physiol Pharmacol 62: 235–240.
25. Hamann A, Fliser JS, Lowell BB (1996) Decreased brown fat markedly enhances susceptibility to diet-induced obesity, diabetes, and hyperlipidemia. Endocrinology 137: 21–29.
26. Lowell BB, V SS, Hamann A, Lawits JA, Himms-Hagen J, et al. (1993) Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature 366: 740–742.
27. Cousin B, Canti S, Morroni M, Rainhaute S, Ricquier D, et al. (1992) Occurrence of brown adipocytes in rat white adipose tissue: molecular and morphological characterization. J Cell Sci 103( Pt 4): 931–942.
28. Loncar D (1994) Convertible adipose tissue in mice. Cell Tissue Res 266: 149–161.
29. Guerra C, Koza RA, Yamashita H, Walsh K, Kozak LP (1988) Emergence of brown adipocytes in white fat in mice is under genetic control. Effects on body weight and adiposity. J Clin Invest 102: 412–420.
30. Ricquier D, Nechad M, Mory G (1982) Ultrastructural and biochemical characterization of human brown adipose tissue in pheochromocytoma. J Clin Endocrinol Metab 54: 803–807.
31. Lean ME, James WP, Jennings G, Trayhurn P (1986) Brown adipose tissue in patients with phaeochromocytoma. Int J Obes 10: 219–227.
32. Daniels SR, Khoury PR, Morrison JA (2000) Utility of different measures of body fat distribution in children and adolescents. Am J Epidemiol 152: 1179–1184.
33. Menke A, Muntner P, Waldman RP, Reynolds K, He J (2007) Measures of adiposity and cardiovascular disease risk factors. Obesity (Silver Spring) 15: 785–795.
34. Omachi A, Matushita Y, Kinumura K, Saito M (2008) Role of uncoupling protein 1 in the anti-obesity effect of beta3-adrenergic agonist in the dog. Res Vet Sci 85: 214–219.
35. Inokuma K, Okamatsu-Ogura Y, Omachi A, Matushita Y, Kinumura K, et al. (2006) Indispensable role of mitochondrial UCP1 for antiobesity effect of beta3-adrenergic stimulation. Am J Physiol Endocrinol Metab 290: E1014–1021.